Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × pCR Rate × Metformin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 22 Breast Neoplasms 21 Polycystic Ovary Syndrome 11 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 10 Lung Neoplasms 8 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Neoplasms 6 Glioblastoma 5 Rectal Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Insulin Resistance 4 Adenocarcinoma of Lung 4 Adenocarcinoma 4 Uterine Cervical Neoplasms 3 Leukoplakia, Oral 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Hyperandrogenism 2 Esophageal Neoplasms 2 Erythroplasia 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Colonic Neoplasms 2 Carcinoma, Ovarian Epithelial 2

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡